140 related articles for article (PubMed ID: 2344861)
21. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach.
Toutain PL; Lefebvre HP; King JN
J Pharmacol Exp Ther; 2000 Mar; 292(3):1087-93. PubMed ID: 10688627
[TBL] [Abstract][Full Text] [Related]
22. Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers.
Chan KK; Buch A; Glazer RD; John VA; Barr WH
Pharm Res; 1994 Mar; 11(3):432-7. PubMed ID: 8008712
[TBL] [Abstract][Full Text] [Related]
23. Steady-state pharmacokinetics and pharmacodynamics of benazeprilat in spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats.
LeRoy S; Berner B
Pharm Res; 1991 Jul; 8(7):883-7. PubMed ID: 1924139
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs.
Mochel JP; Fink M; Peyrou M; Soubret A; Giraudel JM; Danhof M
Pharm Res; 2015 Jun; 32(6):1931-46. PubMed ID: 25446774
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous determination of benazepril hydrochloride and benazeprilat in plasma by high-performance liquid chromatography/electrospray-mass spectrometry.
Xiao W; Chen B; Yao S; Cheng Z
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jan; 814(2):303-8. PubMed ID: 15639452
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers.
Emmons GT; Argenti R; Martin LL; Martin NE; Jensen BK
J Clin Pharmacol; 2004 Aug; 44(8):901-5. PubMed ID: 15286094
[TBL] [Abstract][Full Text] [Related]
27. A pharmacokinetic study of cilazapril in elderly and young volunteers.
Williams PE; Brown AN; Rajaguru S; Walters GE; McEwen J; Durnin C
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):211S-215S. PubMed ID: 2527535
[TBL] [Abstract][Full Text] [Related]
28. Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites.
Lefebvre HP; Laroute V; Concordet D; Toutain PL
J Vet Intern Med; 1999; 13(1):21-7. PubMed ID: 10052059
[TBL] [Abstract][Full Text] [Related]
29. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: case of enalapril and benazepril in dogs.
Toutain PL; Lefebvre HP; Laroute V
J Pharmacol Exp Ther; 2000 Mar; 292(3):1094-103. PubMed ID: 10688628
[TBL] [Abstract][Full Text] [Related]
30. Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.
Cawello W; Boekens H; Waitzinger J; Miller U
Int J Clin Pharmacol Ther; 2002 Jan; 40(1):9-17. PubMed ID: 11837383
[TBL] [Abstract][Full Text] [Related]
31. Disposition of [14C]-benazepril hydrochloride in rat, dog and baboon. Absorption, distribution, kinetics, biotransformation and excretion.
Waldmeier F; Schmid K
Arzneimittelforschung; 1989 Jan; 39(1):62-7. PubMed ID: 2719745
[TBL] [Abstract][Full Text] [Related]
32. Antihypertensive mechanism of action of the novel angiotensin converting enzyme inhibitor benazepril. Effect on isolated vascular preparations.
Kuroda K; Fukuda Y; Nakao K; Inukai T
Arzneimittelforschung; 1990 Sep; 40(9):968-73. PubMed ID: 2080946
[TBL] [Abstract][Full Text] [Related]
33. Bioequivalence of a new liquid formulation of benazepril compared with the reference tablet product.
Kelers K; Devi JL; Anderson GA; Zahra P; Vine JH; Whittem T
Aust Vet J; 2013 Aug; 91(8):312-9. PubMed ID: 23889096
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to young and elderly patients with mild-to-moderate hypertension.
Arner P; Wade A; Engfeldt P; Mouren M; Stepniewski JP; Sultan E; Bryce T; Lenfant B
J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S44-9. PubMed ID: 7527101
[TBL] [Abstract][Full Text] [Related]
35. Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics.
O'Grady P; Yee KF; Lins R; Mangold B
Br J Clin Pharmacol; 1999 Sep; 48(3):375-81. PubMed ID: 10510149
[TBL] [Abstract][Full Text] [Related]
36. Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure.
Balfour JA; Goa KL
Drugs; 1991 Sep; 42(3):511-39. PubMed ID: 1720384
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and biochemical efficacy of idrapril calcium, a novel ACE inhibitor, after multiple oral administration in humans.
Wyld PJ; Grant J; Lippi A; Criscuoli M; Del Re G; Subissi A
Br J Clin Pharmacol; 1994 Nov; 38(5):421-5. PubMed ID: 7893583
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and tolerability of a new manidipine and delapril fixed oral combination in young and elderly subjects.
Stockis A; De Bruyn S; Gengler C; Goethals F; Lens S; Poli G; Acerbi D
Arzneimittelforschung; 2003; 53(8):554-61. PubMed ID: 13677245
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.
Liao WC; Vesterqvist O; Delaney C; Jemal M; Ferreira I; Ford N; Swanson B; Uderman H
Br J Clin Pharmacol; 2003 Oct; 56(4):395-406. PubMed ID: 12968984
[TBL] [Abstract][Full Text] [Related]
40. Determination of benazepril, a new angiotensin-converting enzyme inhibitor, and its active metabolite, benazeprilat, in plasma and urine by capillary gas chromatography-mass-selective detection.
Sioufi A; Pommier F; Kaiser G; Dubois JP
J Chromatogr; 1988 Dec; 434(1):239-46. PubMed ID: 3243821
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
